Replies to post #123629 on Biotech Values

[genisi]

In other words (my nitpick), Neugranin does not infringe on AMGN’s methods for PEGylating G-CSF patents, but it does infringe on AMGN’s G-CSF protein sequences patents.
I believe that lipegfilgrastim, the Neulasta knockoff from Ratiopharm, also has the same amino acid sequence protected by Amgen's IP and might (haven't looked deep into the methods for PEGylating G-CSF patents and not sure if linking the peg polymer to carbohydrate (glycan) is covered by those) face another hurdle with the PEGylating G-CSF patents that are running till 2015. Your point that lipegfilgrastim was not included in the settlement and the above makes me think it will not be launched in the US at least before patents expiration.